Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine + Low-Dose Cytarabine in Newly Diagnosed CML
NCT00003694Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 1999
- Primary completion
- Aug 2003
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of homoharringtonine in chronic myeloid leukemia (CML), sponsored by National Cancer Institute. Primary endpoint: Complete cytogenetic, major cytogenetic, and hematologic response rate at 9 months. Started Mar 1999; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00003694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003694.